3.064EUR-2.54%Mkt Cap: 241.61M EURP/E: —Last update: 2026-06-01
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap241.61M EUR
Enterprise Value—
Revenue (TTM)12.61M EUR
Gross Profit12.51M EUR
Net Income (TTM)-3.06M EUR
Revenue/Share0.1630 EUR
Last Price3.064 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees46
CountryES
SectorHealthcare
IndustryBiotechnology
ISINES0167733015
Valuation
P/E (Trailing)—
P/E (Forward)224.57
PEG—
EV/EBITDA—
EV/Revenue—
P/S19.66
P/B2.07
EPS (TTM)-0.03
EPS (Forward)0.01
52W Range
2.55535% of range4.020
52W High4.020 EUR
52W Low2.555 EUR
Profitability
Gross Margin97.42%
Oper. Margin-75.34%
EBITDA Margin-74.28%
Profit Margin-20.43%
ROE-2.21%
ROA-1.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.77M EUR
CapEx (TTM)12.97M EUR
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.06
Current Ratio—
Quick Ratio—
Book Value/Sh1.520 EUR
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)7.133 EUR
Target Range4.200 EUR – 12.00 EUR
# Analysts3
Ownership
Shares Out.77.51M
Float60.52M
Insiders21.27%
Institutions0.90%
Technical
SMA 502.835 (+8.1%)
SMA 2003.037 (+0.9%)
Beta0.43
S&P 52W Chg27.94%
Avg Vol (30d)374.61K
Avg Vol (10d)526.71K
Technical Indicators
RSI (14)73.1
MACD0.0807
MACD Signal0.0469
MACD Hist.+0.0339
BB Upper3.184 EUR
BB Middle2.893 EUR
BB Lower2.603 EUR
BB Width20.11%
ATR (14)0.0982 EUR
Vol Ratio (20d)2.86x